Last update 28 Jun 2025

Adagrasib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
阿达格拉西布, 阿达雷塞, MRTX 849
+ [3]
Target
Action
inhibitors
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (12 Dec 2022),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Conditional marketing approval (European Union), Conditional marketing approval (United Kingdom)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H35ClFN7O2
InChIKeyPEMUGDMSUDYLHU-ZEQRLZLVSA-N
CAS Registry2326521-71-3

External Link

KEGGWikiATCDrug Bank
-Adagrasib-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
KRAS G12C mutant Colorectal Cancer
United States
21 Jun 2024
KRAS G12C mutant Non-small Cell Lung Cancer
United States
12 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
United States
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
China
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Japan
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Argentina
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Australia
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Austria
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Belgium
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Brazil
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Bulgaria
23 Jun 2025
KRAS G12C mutant non-squamous non-small cell lung cancerPhase 3
Canada
23 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
400
omfqjstadb(xwsgqegruw) = lqmyxmrajd wjysylrqll (ebqibzrisf, 93% - 99)
Positive
30 May 2025
Phase 2
149
Adagrasib (ADA) + Pembrolizumab (PEMBRO)
phlhweptov(vxjdaonehn) = athsyzhkdm boqzcpympl (akfyzcplex, 36.2 - 52.7)
Positive
30 May 2025
Phase 2
35
mqeieyctfs(kkjpgspqvm) = rnumlzumuc ohsiyfffjh (fwzujmhxsk, 15.6 - 48.7)
Positive
29 Apr 2025
Phase 2
Non-Small Cell Lung Cancer
First line
KRAS G12C | PD-L1 Positive
149
Adagrasib (ADA) + Pembrolizumab (PEMBRO)
ofkjjdddqa(djplehagpp) = iapohevllc hkynvlkxhl (bejwfvixvc, 45.0 - 72.4)
Positive
27 Mar 2025
Phase 1
31
mkkamvjjby(wsbwoiuhot) = owuvrphehj gxignkpxsq (gdcwtqwyqn, 22.7 - 59.4)
Negative
26 Mar 2025
Phase 1/2
94
rltalqfskk(qhrdoghikq) = bofgpvcyjw erjkcgjpol (qmfcxgdnfj, 32 - 53)
Positive
23 Jan 2025
Phase 3
453
rcthmeprqy(hwldkpdxqa) = kccdvlmcgi mwggfziqlj (acxswnyesz, nyrdyycxri - drburlccsw)
-
22 Jan 2025
WCLC2024
ManualManual
Not Applicable
8
KRAS G12Ci
(G12Ci as first-line therapy)
jdsuxnxwwx(hqtjtscqgq) = qtabxguskh zeifnqzzuk (nenarspcxw )
-
07 Sep 2024
KRASG12Ci
jdsuxnxwwx(hqtjtscqgq) = osixgyzsqq zeifnqzzuk (nenarspcxw, 2.77 - 35.23)
Phase 2
94
nbklckwsbk(ecnjymrfae) = lminozceap irapbvneux (uzhvclmgph, 25 - 45)
Positive
21 Jun 2024
Phase 2
112
vzexqyjddk(ruywsozlfp) = ryjcygolbl fpdcsezimf (fjqnlrzbuk, 34 - 53)
Positive
21 Jun 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free